BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hallsworth K, Adams LA. Lifestyle modification in NAFLD/NASH: Facts and figures. JHEP Rep 2019;1:468-79. [PMID: 32039399 DOI: 10.1016/j.jhepr.2019.10.008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 11.3] [Reference Citation Analysis]
Number Citing Articles
1 Cariou B, Byrne CD, Loomba R, Sanyal AJ. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obes Metab 2021;23:1069-83. [PMID: 33464677 DOI: 10.1111/dom.14322] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
2 Francque SMA. Top level research in hepatology: COVID-19 and beyond. JHEP Rep 2021;3:100302. [PMID: 33969283 DOI: 10.1016/j.jhepr.2021.100302] [Reference Citation Analysis]
3 Viveiros K. The Role of Life Style Modifications in Comprehensive Non-Alcoholic Fatty Liver Disease Treatment. Clin Liver Dis (Hoboken) 2021;17:11-4. [PMID: 33552479 DOI: 10.1002/cld.1007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
4 Ferraioli G, Berzigotti A, Barr RG, Choi BI, Cui XW, Dong Y, Gilja OH, Lee JY, Lee DH, Moriyasu F, Piscaglia F, Sugimoto K, Wong GL, Wong VW, Dietrich CF. Quantification of Liver Fat Content with Ultrasound: A WFUMB Position Paper. Ultrasound Med Biol 2021;47:2803-20. [PMID: 34284932 DOI: 10.1016/j.ultrasmedbio.2021.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Simón J, Delgado TC, Martinez-Cruz LA, Martínez-Chantar ML. Magnesium, Little Known But Possibly Relevant: A Link between NASH and Related Comorbidities. Biomedicines 2021;9:125. [PMID: 33513920 DOI: 10.3390/biomedicines9020125] [Reference Citation Analysis]
6 Stine JG, Soriano C, Schreibman I, Rivas G, Hummer B, Yoo E, Schmitz K, Sciamanna C. Breaking Down Barriers to Physical Activity in Patients with Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2021;66:3604-11. [DOI: 10.1007/s10620-020-06673-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
7 Bhandari P, Sapra A, Ajmeri MS, Albers CE, Sapra D. Nonalcoholic Fatty Liver Disease: Could It Be the Next Medical Tsunami? Cureus. [DOI: 10.7759/cureus.23806] [Reference Citation Analysis]
8 Semmler G, Datz C, Reiberger T, Trauner M. Diet and exercise in NAFLD/NASH: Beyond the obvious. Liver Int 2021. [PMID: 34328248 DOI: 10.1111/liv.15024] [Reference Citation Analysis]
9 Chen Y, Lian C, Sun Q, Wang T, Liu Y, Ye J, Gao L, Yang Y, Liu S, Shen Z, Liu Y. Ramulus Mori (Sangzhi) Alkaloids Alleviate High-Fat Diet-Induced Obesity and Nonalcoholic Fatty Liver Disease in Mice. Antioxidants 2022;11:905. [DOI: 10.3390/antiox11050905] [Reference Citation Analysis]
10 Gerges SH, Wahdan SA, Elsherbiny DA, El-Demerdash E. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. Life Sci 2021;271:119220. [PMID: 33592199 DOI: 10.1016/j.lfs.2021.119220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Sampson CM, Dimet AL, Neelakantan H, Ogunseye KO, Stevenson HL, Hommel JD, Watowich SJ. Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice. Sci Rep 2021;11:5637. [PMID: 33707534 DOI: 10.1038/s41598-021-85051-6] [Reference Citation Analysis]
12 Santos-laso A, Gutiérrez-larrañaga M, Alonso-peña M, Medina JM, Iruzubieta P, Arias-loste MT, López-hoyos M, Crespo J. Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets. Biomedicines 2022;10:46. [DOI: 10.3390/biomedicines10010046] [Reference Citation Analysis]
13 Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol 2021;18:599-612. [PMID: 33972770 DOI: 10.1038/s41575-021-00448-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
14 Martin-Grau M, Marrachelli VG, Monleon D. Rodent models and metabolomics in non-alcoholic fatty liver disease: What can we learn? World J Hepatol 2022; 14(2): 304-318 [DOI: 10.4254/wjh.v14.i2.304] [Reference Citation Analysis]
15 Abdelmalek MF, Charles ED, Sanyal AJ, Harrison SA, Neuschwander-Tetri BA, Goodman Z, Ehman RA, Karsdal M, Nakajima A, Du S, Tirucherai GS, Klinger GH, Mora J, Yamaguchi M, Shevell DE, Loomba R. The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. Contemp Clin Trials 2021;104:106335. [PMID: 33657443 DOI: 10.1016/j.cct.2021.106335] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Saiman Y, Serper M. Frailty and Sarcopenia in Patients Pre- and Post-Liver Transplant. Clin Liver Dis 2021;25:35-51. [PMID: 33978582 DOI: 10.1016/j.cld.2020.08.004] [Reference Citation Analysis]
17 Wang G, Wu B, Zhang L, Jin X, Wang K, Xu W, Zhang B, Wang H. The protective effects of trelagliptin on high-fat diet-induced nonalcoholic fatty liver disease in mice. J Biochem Mol Toxicol 2021;35:e22696. [PMID: 33421258 DOI: 10.1002/jbt.22696] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Rao AS, Hegde S, Pacioretty LM, DeBenedetto J, Babish JG. Nigella sativa and Trigonella foenum-graecum Supplemented Chapatis Safely Improve HbA1c, Body Weight, Waist Circumference, Blood Lipids, and Fatty Liver in Overweight and Diabetic Subjects: A Twelve-Week Safety and Efficacy Study. J Med Food 2020;23:905-19. [PMID: 32758056 DOI: 10.1089/jmf.2020.0075] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Levy JJ, Azizgolshani N, Andersen MJ Jr, Suriawinata A, Liu X, Lisovsky M, Ren B, Bobak CA, Christensen BC, Vaickus LJ. A large-scale internal validation study of unsupervised virtual trichrome staining technologies on nonalcoholic steatohepatitis liver biopsies. Mod Pathol 2021;34:808-22. [PMID: 33299110 DOI: 10.1038/s41379-020-00718-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
20 Zhang H, Lu J, Liu H, Guan L, Xu S, Wang Z, Qiu Y, Liu H, Peng L, Men X. Ajugol enhances TFEB-mediated lysosome biogenesis and lipophagy to alleviate non-alcoholic fatty liver disease. Pharmacol Res 2021;174:105964. [PMID: 34732369 DOI: 10.1016/j.phrs.2021.105964] [Reference Citation Analysis]
21 van den Hoek AM, de Jong JCBC, Worms N, van Nieuwkoop A, Voskuilen M, Menke AL, Lek S, Caspers MPM, Verschuren L, Kleemann R. Diet and exercise reduce pre-existing NASH and fibrosis and have additional beneficial effects on the vasculature, adipose tissue and skeletal muscle via organ-crosstalk. Metabolism 2021;124:154873. [PMID: 34478753 DOI: 10.1016/j.metabol.2021.154873] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Jiao TY, Ma YD, Guo XZ, Ye YF, Xie C. Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease. Acta Pharmacol Sin 2022. [PMID: 35217817 DOI: 10.1038/s41401-022-00880-z] [Reference Citation Analysis]
23 Zhu B, Chan SL, Li J, Li K, Wu H, Cui K, Chen H. Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment. Front Cardiovasc Med 2021;8:742382. [PMID: 34557535 DOI: 10.3389/fcvm.2021.742382] [Reference Citation Analysis]
24 Smeuninx B, Boslem E, Febbraio MA. Current and Future Treatments in the Fight Against Non-Alcoholic Fatty Liver Disease. Cancers (Basel) 2020;12:E1714. [PMID: 32605253 DOI: 10.3390/cancers12071714] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
25 Kartasheva-Ebertz DM, Pol S, Lagaye S. Retinoic Acid: A New Old Friend of IL-17A in the Immune Pathogeny of Liver Fibrosis. Front Immunol 2021;12:691073. [PMID: 34211477 DOI: 10.3389/fimmu.2021.691073] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Chhimwal J, Patial V, Padwad Y. Beverages and Non-alcoholic fatty liver disease (NAFLD): Think before you drink. Clin Nutr 2021;40:2508-19. [PMID: 33932796 DOI: 10.1016/j.clnu.2021.04.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Gerges SH, Wahdan SA, Elsherbiny DA, El-demerdash E. Diosmin ameliorates inflammation, insulin resistance, and fibrosis in an experimental model of non-alcoholic steatohepatitis in rats. Toxicology and Applied Pharmacology 2020;401:115101. [DOI: 10.1016/j.taap.2020.115101] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
28 Skat-rørdam J, Pedersen K, Skovsted GF, Gregersen I, Vangsgaard S, Ipsen DH, Latta M, Lykkesfeldt J, Tveden-nyborg P. Vitamin C Deficiency May Delay Diet-Induced NASH Regression in the Guinea Pig. Antioxidants 2022;11:69. [DOI: 10.3390/antiox11010069] [Reference Citation Analysis]
29 Zhu Y, Peng Z, Lu Y, Li H, Zeng X, Zhang Z, Li X, Hu C, Hu A, Zhao Q, Wang H, Yang W. Higher dietary insulinaemic potential is associated with increased risk of liver steatosis and fibrosis. Liver Int 2021. [PMID: 34521152 DOI: 10.1111/liv.15057] [Reference Citation Analysis]
30 O'Gorman P, Monaghan A, McGrath M, Naimimohasses S, Gormley J, Norris S. Determinants of Physical Activity Engagement in Patients With Nonalcoholic Fatty Liver Disease: The Need for an Individualized Approach to Lifestyle Interventions. Phys Ther 2021;101:pzaa195. [PMID: 33104787 DOI: 10.1093/ptj/pzaa195] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Kemas AM, Youhanna S, Lauschke VM. Non-alcoholic fatty liver disease - opportunities for personalized treatment and drug development. Expert Review of Precision Medicine and Drug Development 2022;7:39-49. [DOI: 10.1080/23808993.2022.2053285] [Reference Citation Analysis]
32 Tacke F, Weiskirchen R. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. Ann Transl Med 2021;9:729. [PMID: 33987427 DOI: 10.21037/atm-20-4354] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 Słomko J, Zalewska M, Niemiro W, Kujawski S, Słupski M, Januszko-Giergielewicz B, Zawadka-Kunikowska M, Newton J, Hodges L, Kubica J, Zalewski P. Evidence-Based Aerobic Exercise Training in Metabolic-Associated Fatty Liver Disease: Systematic Review with Meta-Analysis. J Clin Med 2021;10:1659. [PMID: 33924482 DOI: 10.3390/jcm10081659] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Colosimo S, Ravaioli F, Petroni ML, Brodosi L, Marchignoli F, Barbanti FA, Sasdelli AS, Marchesini G, Pironi L. Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis. Liver Int 2021;41:731-42. [PMID: 33497019 DOI: 10.1111/liv.14799] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
35 Mokhtari E, Farhadnejad H, Salehi-Sahlabadi A, Najibi N, Azadi M, Teymoori F, Mirmiran P. Spinach consumption and nonalcoholic fatty liver disease among adults: a case-control study. BMC Gastroenterol 2021;21:196. [PMID: 33933019 DOI: 10.1186/s12876-021-01784-8] [Reference Citation Analysis]
36 Zhao J, Bai M, Wei S, Li C, Lv Q, Chen Y. Improvement of Non-Alcoholic Fatty Liver Disease in Mice by Intermittent Use of a Fasting-Mimicking Diet. Mol Nutr Food Res 2021;65:e2100381. [PMID: 34632700 DOI: 10.1002/mnfr.202100381] [Reference Citation Analysis]
37 Hallsworth K, Gosrani S, Hogg S, Patel P, Wetten A, Welton R, McPherson S, Campbell MD. Association of exercise participation levels with cardiometabolic health and quality of life in individuals with hepatitis C. BMJ Open Gastroenterol 2021;8:e000591. [PMID: 33762303 DOI: 10.1136/bmjgast-2020-000591] [Reference Citation Analysis]
38 Francque SM, Marchesini G, Kautz A, Walmsley M, Dorner R, Lazarus JV, Zelber-Sagi S, Hallsworth K, Busetto L, Frühbeck G, Dicker D, Woodward E, Korenjak M, Willemse J, Koek GH, Vinker S, Ungan M, Mendive JM, Lionis C. Non-alcoholic fatty liver disease: A patient guideline. JHEP Rep 2021;3:100322. [PMID: 34693236 DOI: 10.1016/j.jhepr.2021.100322] [Reference Citation Analysis]
39 Cigrovski Berkovic M, Bilic-Curcic I, Mrzljak A, Cigrovski V. NAFLD and Physical Exercise: Ready, Steady, Go! Front Nutr 2021;8:734859. [PMID: 34676233 DOI: 10.3389/fnut.2021.734859] [Reference Citation Analysis]
40 Hallsworth K, McPherson S, Anstee QM, Flynn D, Haigh L, Avery L. Digital Intervention With Lifestyle Coach Support to Target Dietary and Physical Activity Behaviors of Adults With Nonalcoholic Fatty Liver Disease: Systematic Development Process of VITALISE Using Intervention Mapping. J Med Internet Res 2021;23:e20491. [PMID: 33448929 DOI: 10.2196/20491] [Reference Citation Analysis]
41 Barroso WA, Serra MB, Abreu IC, Barbeiro HV, Fiamoncini J, de Alvarenga JFR, de Souza HP, de Lima TM. Banana green peels extract protects against nonalcoholic fatty liver disease in high-fat-fed mice through modulation of lipid metabolism and inflammation. Phytother Res 2022. [PMID: 35018684 DOI: 10.1002/ptr.7366] [Reference Citation Analysis]
42 Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, Kassir R, Singhal R, Mahawar K, Ramnarain D. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord 2022;22:63. [PMID: 35287643 DOI: 10.1186/s12902-022-00980-1] [Reference Citation Analysis]